Auris Medical Holding AG (EARS)’s Financial Results Comparing With Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE)

As Biotechnology businesses, Auris Medical Holding AG (NASDAQ:EARS) and Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE), are affected by contrast. This especially applies to their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Auris Medical Holding AG N/A 0.00 N/A -1.94 0.00
Zynerba Pharmaceuticals Inc. N/A 0.00 40.24M -2.88 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Auris Medical Holding AG and Zynerba Pharmaceuticals Inc.

Profitability

Table 2 demonstrates the return on assets, net margins and return on equity of Auris Medical Holding AG and Zynerba Pharmaceuticals Inc.

Net Margins Return on Equity Return on Assets
Auris Medical Holding AG 0.00% 630.2% -100.9%
Zynerba Pharmaceuticals Inc. 0.00% -74.8% -63.3%

Volatility & Risk

Auris Medical Holding AG’s volatility measures that it’s 207.00% more volatile than Standard and Poor’s 500 due to its -1.07 beta. Competitively, Zynerba Pharmaceuticals Inc. is 333.00% more volatile than Standard and Poor’s 500, because of the 4.33 beta.

Liquidity

The current Quick Ratio of Auris Medical Holding AG is 0.9 while its Current Ratio is 0.9. Meanwhile, Zynerba Pharmaceuticals Inc. has a Current Ratio of 8 while its Quick Ratio is 8. Zynerba Pharmaceuticals Inc. is better positioned to pay off its short-term and long-term debts than Auris Medical Holding AG.

Insider & Institutional Ownership

The shares of both Auris Medical Holding AG and Zynerba Pharmaceuticals Inc. are owned by institutional investors at 11.3% and 18.4% respectively. Competitively, 3.4% are Zynerba Pharmaceuticals Inc.’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Auris Medical Holding AG -8.82% -24.41% 97.3% -54.81% -86.45% -90.97%
Zynerba Pharmaceuticals Inc. -4.15% -23.26% -32.85% -59.08% -60.78% -63.1%

For the past year Auris Medical Holding AG’s stock price has bigger decline than Zynerba Pharmaceuticals Inc.

Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss. The company is also developing AM-125 for the treatment of vestibular disorders; and other pre-clinical stage products comprising AM-102 and AM-123. It has a collaboration and license agreement with Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. The company was formerly known as Auris Medical AG and changed its name to Auris Medical Holding AG in April 2014. Auris Medical Holding AG was founded in 1998 and is headquartered in Zug, Switzerland.

Zynerba Pharmaceuticals, Inc., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates include ZYN002, which is in Phase II clinical trial for adult patients with refractory epileptic focal seizures and osteoarthritis, as well as pediatric patients with fragile X syndrome; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.